Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Common Equity (2023 - 2025)

Immunome (IMNM) has disclosed Common Equity for 3 consecutive years, with $634.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 250.15% year-over-year to $634.3 million, compared with a TTM value of $634.3 million through Dec 2025, up 250.15%, and an annual FY2025 reading of $634.3 million, up 250.15% over the prior year.
  • Common Equity was $634.3 million for Q4 2025 at Immunome, up from $263.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $634.3 million in Q4 2025 and bottomed at $6.1 million in Q3 2023.
  • Average Common Equity over 3 years is $213.3 million, with a median of $234.4 million recorded in 2024.
  • The sharpest move saw Common Equity soared 3436.97% in 2024, then increased 6.08% in 2025.
  • Year by year, Common Equity stood at $119.9 million in 2023, then soared by 51.12% to $181.2 million in 2024, then skyrocketed by 250.15% to $634.3 million in 2025.
  • Business Quant data shows Common Equity for IMNM at $634.3 million in Q4 2025, $263.9 million in Q3 2025, and $269.3 million in Q2 2025.